PhorMed
Utilizing gene therapy to target cancer and mutated cells
Overview
Raised: $2,450,528
Total Commitments ($USD)
StartEngine
12/05/2019
03/25/2022
$250
Equity - Common
Pre-Seed
RegCF
$1.00
$39,000,000
Rolling Commitments ($USD)
03/30/2022
$2,917
4,097
2019
Healthcare & Pharmaceuticals
Biotech
B2B2C
High
High
Summary Profit and Loss Statement
| Most Recent Year | Prior Year | |
|---|---|---|
|
Revenue |
$0 |
$0 |
|
COGS |
$0 |
$0 |
|
Tax |
$0 |
$0 |
| ||
| ||
|
Net Income |
$0 |
$0 |
Summary Balance Sheet
| Most Recent Year | Prior Year | |
|---|---|---|
|
Cash |
$0 |
$0 |
|
Accounts Receivable |
$0 |
$0 |
|
Total Assets |
$0 |
$0 |
|
Short-Term Debt |
$0 |
$0 |
|
Long-Term Debt |
$0 |
$0 |
|
Total Liabilities |
$0 |
$0 |
Raise History
| Offering Name | Close Date | Platform | Valuation/Cap | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|---|
| PhorMed | 04/28/2024 | Wefunder | $52,523,767 | $0 | Equity - Common | Active | RegCF |
| PhorMed | 08/16/2022 | StartEngine | $51,647,023 | $243,864 | Equity - Common | Funded | RegCF |
| PhorMed | 03/24/2022 | StartEngine | $39,000,000 | $2,450,528 | Equity - Common | Funded | RegCF |
Price per Share History
Note: Share prices shown in earlier rounds may not be indicative of any stock splits.
Valuation History
Revenue History
Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.
Employee History
Upgrade to gain access
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
